

1 Effect of Neutrophil Elastase Inhibitor (Sivelestat Sodium) on Oxygenation in Patients with Sepsis  
2 Induced Acute Respiratory Distress Syndrome

3

4 Tiejun Wu<sup>1#\*</sup>, Tao Wang<sup>2#</sup>, Jinjiao Jiang<sup>3</sup>, Yue Tang<sup>3</sup>, Lina Zhang<sup>1</sup>, Zhiming Jiang<sup>4</sup>, Fen Liu<sup>4</sup>,  
5 Guiqing Kong<sup>2</sup>, Tingfa Zhou<sup>5</sup>, Ruijin Liu<sup>5</sup>, Haipeng Guo<sup>6</sup>, Jie Xiao<sup>6</sup>, Wenqing Sun<sup>7</sup>, Yuye Li<sup>7</sup>,  
6 Yingying Zhu<sup>8</sup>, Quan Liu<sup>8</sup>, Weifeng Xie<sup>9</sup>, Yan Qu<sup>9</sup>, Xiaozhi Wang<sup>2\*</sup>.

7

8 1. Department of Critical Care Medicine, Liaocheng People's Hospital, Liaocheng 252004, China.

9 2. Department of Critical Care Medicine, Affiliated Hospital of Binzhou Medical College, Binzhou  
10 256699, China.

11 3. Department of Critical Care Medicine, Provincial Hospital of Shandong First Medical University,  
12 Jinan 250021, China.

13 4. Department of Critical Care Medicine, The First Affiliated Hospital of Shandong First Medical  
14 University, Jinan 250013, China.

15 5. Department of Critical Care Medicine, Linyi People's Hospital, Linyi 276034, China.

16 6. Department of Critical Care Medicine, Qilu Hospital of Shandong University, Jinan 250012,  
17 China.

18 7. Department of Respiratory intensive care unit, Shandong Public Health Clinical Centre, Jinan  
19 250102, China.

20 8. Department of Critical Care Medicine, Tai'an Central Hospital, Taian 271002, China.

21 9. Department of Critical Care Medicine, Qingdao Municipal Hospital, Qingdao 266071, China.

22 # These authors contributed equally to this work.

23 \* Corresponding author,

24 Xiaozhi Wang Email: [hxicuwxz@163.com](mailto:hxicuwxz@163.com).

25 Tiejun Wu Email: [tiejunwu@hotmail.com](mailto:tiejunwu@hotmail.com)

26

27

28

29

30

31

32 **Abstract**

33 Objectives: Neutrophil elastase (NE) plays an important role in the development of acute  
34 respiratory distress syndrome (ARDS). Sivelestat sodium, as a selective NE inhibitor, may  
35 improve the outcomes of patients with sepsis-induced ARDS in previous studies, but there is a  
36 lack of solid evidence. This trial aimed to evaluate the effect of sivelestat sodium on oxygenation  
37 in patients with sepsis-induced ARDS.

38 Methods: We conducted a multicenter, double-blind, randomized, placebo-controlled trial  
39 enrolling patients diagnosed with sepsis-induced ARDS admitted within 48 hours of the advent of  
40 symptoms. Patients were randomized in a 1:1 fashion to sivelestat or placebo. Trial drugs were  
41 administrated as a 24-hour continuous intravenous infusion for a minimum duration of 5 days and  
42 a maximum duration of 14 days. The primary outcome was PaO<sub>2</sub>/FiO<sub>2</sub> ratio improvement on Day5  
43 after randomization, defined by a greater than 50% improvement in PaO<sub>2</sub>/FiO<sub>2</sub> compared with that  
44 on ICU admission or PaO<sub>2</sub>/FiO<sub>2</sub> reached over 300 mmHg on Day5.

45 Results: The study was stopped midway due to a potential between-group difference in mortality  
46 observed during the interim analysis. Overall, a total of 70 patients were randomized, of whom 34  
47 were assigned to receive sivelestat sodium and 36 placebo. On day5, 19/34 (55.9%) patients in the  
48 sivelestat group had PaO<sub>2</sub>/FiO<sub>2</sub> ratio improvement compared with 7/36 (19.4%) patients in the  
49 placebo group (risk difference, 0.36; 95% CI, 0.14 to 0.56, *p*<0.001). The Kaplan-Meier curves  
50 showed a significantly improved 28-day survival rate in patients receiving sivelestat than those not  
51 (hazard ratio, 0.32; 95% CI, 0.11 to 0.95; *p*=0.041).

52 Conclusion: In patients with sepsis-induced ARDS, sivelestat sodium could improve oxygenation  
53 within the first five days and may be associated with decreased 28-day mortality.

54 **Keywords:** sepsis; acute respiratory distress syndrome; neutrophil elastase; sivelestat;  
55 oxygenation.

56

57

58

59

60

61

62

### 63 **Introduction**

64 Sepsis is an aberrant immune response to an infection and a syndrome characterized by organ  
65 dysfunction[1]. Lung injury is common in sepsis and acute respiratory distress syndrome (ARDS)  
66 is a devastating complication of sepsis[2]. Sepsis is the leading cause of ARDS, accounting for  
67 approximately 75% of patients with ARDS[3], and the outcomes of patients with sepsis-induced  
68 ARDs is worse than those with ARDS from other causes[4, 5]. However, therapies to prevent or  
69 treat sepsis-induced ARDS remain elusive[2].

70 During the pathogenesis of sepsis-induced ARDS, multiple circulating immune cells are activated  
71 and inflammatory mediators are massively released into the circulation, which leads to capillary  
72 endothelium injury in the lungs[6, 7]. Following lung injury, immune cells such as neutrophils are  
73 recruited to the alveolar space and release large amounts of toxic mediators, including neutrophil  
74 elastase(NE)[8, 9]. Previous studies found that systemic inflammatory response syndrome (SIRS)  
75 patients with high NE levels were prone to developing ARDS[10] and elevated NE activity was  
76 also observed in the bronchoalveolar lavage fluid (BALF) of patients with ARDS[11].

77 Sivelestat sodium, a small molecule weight, selective and reversible NE inhibitor, was discovered  
78 in 1990s[12] and may confer protective effects on pulmonary endothelial injury in sepsis animal  
79 models[13-15]. Several clinical studies showed that sivelestat sodium could improve oxygenation,  
80 ameliorate lung injury, and reduce the duration of mechanical ventilation in patients with  
81 sepsis-induced ARDS[16-18]. However, no causal relationship can be implicated due to the  
82 observational nature. Therefore, we conducted a multi-center, randomized controlled study to  
83 evaluate the role of sivelestat sodium on oxygenation in patients with sepsis-induced ARDS.

### 84 **Materials and methods**

#### 85 *Trial design and oversight*

86 We conducted an investigator-initiated, multi-center, double-blind, randomized,  
87 placebo-controlled trial at 12 hospitals across China. The human research ethics committee at each  
88 hospital approved the protocol. Patients or their surrogates provided written informed consent  
89 before enrollment. This trial was designed by the authors, who collected and analyzed the data,  
90 vouched for the accuracy and completeness of the data and the adherence of the trial to the

91 protocol, wrote and agreed on the submission of the manuscript. Shanghai Huilun (Jiangsu)  
92 Pharmaceutical Co., Ltd. supplied the trial drugs but had no role in designing or conducting the  
93 trial, or analysing the data and did not have access to the data before publication. The trial was  
94 registered on the Chinese Clinical Trial Registry (ChiCTR2200056892) before enrollment began.

#### 95 ***Study population***

96 Patients diagnosed with sepsis aged between 18 to 75 years old and with ARDS admitted to any of  
97 the participating sites within 48 hours of ARDS onset were eligible for inclusion. The diagnosis of  
98 sepsis was according to sepsis 3.0 criteria[19] and diagnosis of ARDS was based on Berlin  
99 criteria[20]. Patients were excluded if they were pregnant or lactating women, diagnosed with  
100 neutropenia, received chemotherapeutic agents or immunomodulatory drugs or high-dose  
101 corticosteroid therapy for more than 5 days, with a known history of severe cardiovascular,  
102 respiratory, renal, or hepatic diseases, or had disseminated intravascular coagulation, end-stage  
103 malignancy, mental illness, etc. Detailed inclusion and exclusion criteria were provided in the  
104 Supplementary Protocol.

#### 105 ***Randomization, blinding and interventions***

106 Each eligible participant was assigned randomly from a computer-generated sequence to either the  
107 sivelestat sodium or placebo group in a 1:1 ratio, using a block size of 4 stratified by site. The  
108 random allocation sequence was generated by a third party independent of the study. Allocation  
109 concealment was achieved using blinded medication packs. Participants, data collectors, and  
110 investigators assessing outcome data will be blinded to the treatment allocation.

111 Patients were assigned to receive a 24-hour continuous intravenous infusion of sivelestat sodium  
112 at a rate of 0.2 mg/kg/h, for a minimum duration of 5 days and a maximum duration of 14 days or  
113 a placebo during the same study period. All other treatments were administered at the discretion of  
114 the treating clinicians.

#### 115 ***Trial outcomes***

116 The primary outcome was PaO<sub>2</sub>/FiO<sub>2</sub> ratio improvement on Day5 after randomization. PaO<sub>2</sub>/FiO<sub>2</sub>  
117 ratio improvement on Day5 was defined as a greater than 50% improvement in PaO<sub>2</sub>/FiO<sub>2</sub>  
118 compared with that on ICU admission or PaO<sub>2</sub>/FiO<sub>2</sub> reached over 300 mmHg on Day5. Secondary  
119 outcomes included PaO<sub>2</sub>/FiO<sub>2</sub> ratio on Day3, 5, 7 and 28-day mortality, ventilator free days  
120 (28-VFDs) with 28 days, ICU and hospital free days within 28 days.

121 *Sample size estimation*

122 Based on previous studies[16, 17], it is estimated that 35% of the study patients in the control  
123 group would reach the primary endpoint (oxygenation index improvement on Day5). We  
124 estimated that a sample size of 122 participants could provide 80% power at a two-sided alpha  
125 level of 0.05 to detect an absolute 25% elevation in the primary endpoint from the sivelestat  
126 sodium intervention. The calculation was implemented using the PASS 11.0 software (PASS,  
127 NCSS software, Kaysville, USA). In this trial, we plan to randomize 142 patients in total (71 per  
128 group) after allowing for a less than 15% withdrawal. This study employed one planned interim  
129 analysis that was conducted by an independent Data and Safety Monitoring Board (DSMB) after  
130 the first 70 participants enrolled. This analysis would have led to a recommendation to stop the  
131 trial if concerns about participant safety had been raised.

132 *Statistical analysis*

133 Continuous data were reported as means and standard deviations (SD) when normally distributed  
134 or as medians and interquartile ranges (IQR) when not normally distributed. The normality of  
135 continuous variables will be examined using the Shapiro–Wilk test. Categorical data will be  
136 expressed as numbers and percentages.

137 The primary analysis was based on the intention-to-treat (ITT) population, defined as all enrolled  
138 patients from the participating sites. We used generalized linear model (GLM) to compare the  
139 difference in the primary outcome (PaO<sub>2</sub>/FiO<sub>2</sub> ratio improvement on Day5) between groups. We  
140 analyzed secondary outcomes also using GLM. Risk differences and its 95% confidence interval  
141 (CI) were calculated for categorical variables, and mean differences (95% CI) for continuous  
142 variables. Kaplan–Meier curves were used to compare the 28-day survival curves after  
143 randomization. The difference between two-groups was calculated by tested by log-rank test and  
144 its hazard ratio (HR) and 95% CIs was calculated by Mantel-Cox regression model.

145 Four pre-defined subgroup analyses were conducted for the primary endpoint according to (1) age  
146 (dichotomized at 50 years old), (2) APACHE II score at enrollment (dichotomized at 15), (3)  
147 septic shock at enrollment, and (4) PaO<sub>2</sub>/FiO<sub>2</sub> ratio at enrollment (dichotomized at 200). Adverse  
148 event analyses were reported for all the participants who received the study treatment. Analyses  
149 were conducted using R 4.2.3 software. Statistical tests were two-sided, and p values < 0.05 were  
150 considered statistically significant.

151 **Results**

152 ***Recruitment and baseline characteristics***

153 During the study period, 282 patients with sepsis combined with ARDS were assessed for  
154 eligibility, of whom 70 were enrolled in the trial from nine hospitals across China. The trial  
155 recruitment was halted by the DSMB after the interim analysis owing to observed between-group  
156 difference in mortality, and the DSMB requested to unblind the data. After reviewing the  
157 unblinded data, the DSMB concluded that the trial should be stopped midway due to potential  
158 mortality benefits from the trial intervention, and the trial was then formally stopped. The numbers  
159 of cases from each site were shown in online Supplemental table 1. Among those 70 randomized  
160 patients, 34 were assigned to receive sivelastat sodium and 36 placebo. All randomized  
161 participants completed follow-up and were included in the primary analysis (**Figure 1**).

162 The characteristics of the participants at baseline were evenly distributed between the two trial  
163 groups (**Table 1**). The majority of the trial participants required mechanical ventilation (52/70,  
164 74.3%) at admission. The median (IQR) PaO<sub>2</sub>/FiO<sub>2</sub> ratio was 136.0 (104.2-163.0) mmHg in the  
165 sivelastat group and 161.0 (144.0-195.0) mmHg in the placebo group.

166 ***Primary and secondary outcomes***

167 On day5 after randomization, 19/34 (55.9%) patients in the sivelastat group had PaO<sub>2</sub>/FiO<sub>2</sub> ratio  
168 improvement compared with 7/36 (19.4%) patients in the placebo group (risk difference, 0.36; 95%  
169 CI, 0.14 to 0.56,  $p<0.001$ ). In addition, the PaO<sub>2</sub>/FiO<sub>2</sub> ratio constantly differ between groups on  
170 day3, day5 and day7 (**Table 2**).

171 Patients in the sivelastat group had a median of 21.0 VFDs (IQR, 6.5-24.5) within the first 28 days  
172 compared with 20.0 VFDs (IQR, 0-23.0) for those receiving placebo. The mean difference in  
173 VFDs between groups was 3.9 days (95% CI, -1.9 to 9.7,  $p=0.20$ ). No significant difference in  
174 cumulative event of weaning from mechanical ventilation between treatment groups was observed  
175 (hazard ratio, 1.70; 95% CI, 0.87 to 3.31,  $p=0.12$ , supplementary figure 1). The 28-day mortality  
176 was 3/34 (8.8%) in patients receiving sivelastat and 10/36 (27.8%) in those receiving placebo (risk  
177 difference, -0.19; 95% CI, -0.37 to -0.01,  $p=0.03$ ). The Kaplan-Meier curves showed a  
178 significantly improved survival rate in patients receiving sivelestat than those not (HR, 0.32; 95%  
179 CI, 0.11 to 0.95; log-rank  $p=0.041$ ) (**Figure 2**). The ICU and hospital free days within 28 days  
180 were both comparable between two groups (**Table 2**).

181 ***Subgroup analysis***

182 Subgroup analysis suggested the treatment effect of sivelestat on the primary outcome had trends  
183 toward more significant in patients with age $\geq$ 50, with APACHE II score $<$ 15, without septic shock  
184 and with PaO<sub>2</sub>/FiO<sub>2</sub> ratio $\geq$ 200 at enrollment (**Figure 3**).

185 ***Adverse events***

186 The number of adverse events did not differ meaningfully between the trial groups. Details  
187 regarding adverse events are provided in **Table 2**.

188 **Discussion**

189 In this multicenter, double-blind, randomized, placebo-controlled trial, the use of sivelestat sodium  
190 could improve oxygenation within the first week in patients with sepsis-induced ARDS. Moreover,  
191 it was associated with decreased 28-day mortality, though there is no difference in ventilator-free  
192 days or other outcomes. Subgroup analysis showed that age, the baseline respiratory function,  
193 disease severity and septic status may affect the efficacy of sivelestat sodium, favouring sivelestat  
194 use in patients with age $\geq$ 50, with APACHE II score $<$ 15, with PaO<sub>2</sub>/FiO<sub>2</sub> ratio $\geq$ 200, and without  
195 septic shock.

196 Two large clinical trials demonstrated discordant effects of sivelestat sodium in patients with acute  
197 lung injury (ALI)[21, 22]. The phase III Japanese study by Tamakuma et al. included 230  
198 ALI/ARDS patients combined with SIRS, and sivelestat was shown to increase pulmonary  
199 function, reduce duration of mechanical ventilation, and shorten ICU stay[21]. An international  
200 multicenter double-blind, placebo-controlled Phase II study (STRIVE study) randomized 492  
201 mechanically ventilated patients with ALI/ARDS[22], and the results showed that sivelestat did  
202 not change 28-day mortality or VFDs. Furthermore, a negative trend in long-term 180-day  
203 mortality rate was noted, and the trial was then stopped midway per the recommendation from the  
204 DSMB.

205 The discrepancy between the two studies may be due to differences in the characteristics of study  
206 patients, such as age, baseline respiratory function, disease severity and septic status. The patients  
207 enrolled in the phase III Japanese study had a narrower age distribution and better respiratory  
208 function than those in the STRIVE study. In addition, clinical studies reporting positive results  
209 with sivelestat therapy had mainly enrolled ARDS patients with a Lung Injury Score  $<$ 2.5,  
210 whereas the majority of the patients in the STRIVE study had a Lung Injury Score  $>$ 2.5[23, 24]. A

211 post-hoc analysis of the STRIVE patients involving those who had a mean Lung Injury Score $\leq$ 2.5,  
212 revealed favourable trends in mortality and VFDs in patients receiving sivelestat[22]. On the other  
213 hand, it is suggested that the different proportions of septic patients may have contributed to the  
214 discordant results among these studies (58% vs. 69%). Our results were consistent with the above  
215 findings, showing that sivelestat may confer larger treatment effects in patients with  
216 sepsis-induced ARDS, especially in patients with less severe disease, including those with  
217 APACHE II score $<$ 15 or with PaO<sub>2</sub>/FiO<sub>2</sub> ratio $\geq$ 200 or without septic shock. Taken together, our  
218 study suggests that sivelestat could be effective in patients with mild sepsis-induced ARDS, and  
219 may be associated with survival benefits in this population.

220 The above results can also be explained from a pathophysiological point of view. Neutrophil  
221 activation and NE release are very early biological events in the pathogenesis of ARDS[25].  
222 Previous research showed a significant increase in blood NE in patients with sepsis-induced  
223 ARDS[26] and a decrease in blood NE after sivelestat administration[27, 28], suggesting that the  
224 therapeutic effect of sivelestat is related to the inhibition of NE. Recent studies have shown that  
225 damage to the endothelial glycocalyx is a critical factor in the development and progression of  
226 ARDS[29, 30]. In addition, our preclinical research has shown that sivelestat can reduce  
227 endothelial glycocalyx damage by inhibiting the production of NETs, improve endothelial cell  
228 permeability, attenuate lung histopathological injury and ultimately improve survival in  
229 sepsis-induced ALI model mice. Further molecular docking and visualisation analysis showed that  
230 sivelestat could bind with high affinity to the key ferroptosis protein glutathione peroxidase  
231 (GPX4), increase the expression of GPX4 and thus interfere with the process of ferroptosis[26].  
232 Therefore, sivelestat may have pleiotropic effects on ARDS and may not be limited to interfering  
233 with NE.

234 The trial had several limitations. First, the current sample size was not powered to detect mortality  
235 difference, and stopping the trial midway further weaken the robustness of the results. Thus, the  
236 results of this trial should be interpreted cautiously. Second, subjective factors contribute to the  
237 decision to wean patients from mechanical ventilation, which may bias the VFDs. Third, the  
238 results could be strengthened had more inflammatory mediators and other surrogate measurements,  
239 including IL-6, IL-8, IL-10, TNF- $\alpha$  been measured. Last, we did not observe the effects of  
240 sivelestat on long-term outcomes, like pulmonary function after hospital discharge.



241 **Conclusion**

242 In patients with sepsis-induced ARDS, sivelestat sodium could improve oxygenation within the  
243 first week, and was associated with decreased 28-day mortality, particularly in patients with less  
244 severe disease, including those with APACHE II score <15 or with PaO<sub>2</sub>/FiO<sub>2</sub> ratio ≥200 or without  
245 septic shock. Further large-scale RCTs are needed to confirm the effects of sivelestat on mortality  
246 in this population.

247 **Ethics and approval statement**

248 The protocol and the informed consent document have been reviewed and approved by the  
249 Institutional Ethics Committee of all participating centers. Study investigators will provide  
250 potential participants with verbal and written information prior to inclusion in the study. Informed  
251 consent will be provided from participants or their authorized representatives. The study was  
252 registered in the Clinical Trials Register (ChiCTR2200056892).

253 **Funding**

254 This study is supported by Shanghai Huilun (Jiangsu) Pharmaceutical Co., Ltd., which is also  
255 responsible for the supply of the study drug and placebo as well as distribution to the participating  
256 centers. Funding agency had no input into the design, conduct, data collection, statistical analysis,  
257 or writing of the manuscript.

258 **Authorship contribution statement**

259 Tiejun Wu, Tao Wang and Xiaozhi Wang: drafting of the manuscript; material or technique support;  
260 critical revision of the manuscript. Jinjiao Jiang, Yue Tang, Lina Zhang, Zhiming Jiang, Fen Liu,  
261 Guiqing Kong, Tingfa Zhou, Ruijin Liu, Haipeng Guo, Jie Xiao, Wenqing Sun, Yuye Li, Yingying  
262 Zhu, Quan Liu, Weifeng Xie, Yan Qu: Patient screening and data collection. Xiaozhi Wang:  
263 analysis and interpretation of data. Tiejun Wu and Tao Wang: conceived, designed and supervised the  
264 study; analysis and interpretation of data; critical revision of the manuscript; obtained funding. All authors  
265 have read the manuscript and approved its submission.

266 **Declaration of competing interest**

267 The authors have declared that no competing interest exists.

268 **Reference**

- 269 1. Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, Bellomo R,  
270 Bernard GR, Chiche JD, Cooper-Smith CM *et al*: **The Third International Consensus**

- 271           **Definitions for Sepsis and Septic Shock (Sepsis-3).** *Jama* 2016, **315**(8):801-810.
- 272    2.       Beitler JR, Thompson BT, Baron RM, Bastarache JA, Denlinger LC, Esserman L, Gong MN,  
273       LaVange LM, Lewis RJ, Marshall JC *et al*: **Advancing precision medicine for acute**  
274       **respiratory distress syndrome.** *Lancet Respir Med* 2022, **10**(1):107-120.
- 275    3.       Bellani G, Laffey JG, Pham T, Fan E, Brochard L, Esteban A, Gattinoni L, van Haren F,  
276       Larsson A, McAuley DF *et al*: **Epidemiology, Patterns of Care, and Mortality for Patients**  
277       **With Acute Respiratory Distress Syndrome in Intensive Care Units in 50 Countries.**  
278       *Jama* 2016, **315**(8):788-800.
- 279    4.       Stapleton RD, Wang BM, Hudson LD, Rubenfeld GD, Caldwell ES, Steinberg KP: **Causes**  
280       **and timing of death in patients with ARDS.** *Chest* 2005, **128**(2):525-532.
- 281    5.       Sheu CC, Gong MN, Zhai R, Chen F, Bajwa EK, Clardy PF, Gallagher DC, Thompson BT,  
282       Christiani DC: **Clinical characteristics and outcomes of sepsis-related vs**  
283       **non-sepsis-related ARDS.** *Chest* 2010, **138**(3):559-567.
- 284    6.       Englert JA, Bobba C, Baron RM: **Integrating molecular pathogenesis and clinical**  
285       **translation in sepsis-induced acute respiratory distress syndrome.** *JCI Insight* 2019, **4**(2).
- 286    7.       Xu H, Sheng S, Luo W, Xu X, Zhang Z: **Acute respiratory distress syndrome**  
287       **heterogeneity and the septic ARDS subgroup.** *Front Immunol* 2023, **14**:1277161.
- 288    8.       Zeiber BG, Matsuoka S, Kawabata K, Repine JE: **Neutrophil elastase and acute lung injury:**  
289       **prospects for sivelestat and other neutrophil elastase inhibitors as therapeutics.** *Crit Care*  
290       *Med* 2002, **30**(5 Suppl):S281-287.
- 291    9.       Sahebnasagh A, Saghafi F, Safdari M, Khataminia M, Sadremomtaz A, Talaei Z, Rezai  
292       Ghaleno H, Bagheri M, Habtemariam S, Avan R: **Neutrophil elastase inhibitor (sivelestat)**  
293       **may be a promising therapeutic option for management of acute lung injury/acute**  
294       **respiratory distress syndrome or disseminated intravascular coagulation in COVID-19.**  
295       *J Clin Pharm Ther* 2020, **45**(6):1515-1519.
- 296    10.      Kodama T, Yukioka H, Kato T, Kato N, Hato F, Kitagawa S: **Neutrophil elastase as a**  
297       **predicting factor for development of acute lung injury.** *Intern Med* 2007, **46**(11):699-704.
- 298    11.      McGuire WW, Spragg RG, Cohen AB, Cochrane CG: **Studies on the pathogenesis of the**  
299       **adult respiratory distress syndrome.** *J Clin Invest* 1982, **69**(3):543-553.
- 300    12.      Kawabata K, Suzuki M, Sugitani M, Imaki K, Toda M, Miyamoto T: **ONO-5046, a novel**

- 301            **inhibitor of human neutrophil elastase.** *Biochem Biophys Res Commun* 1991,  
302            **177(2):814-820.**
- 303    13.        Suzuki K, Okada H, Takemura G, Takada C, Kuroda A, Yano H, Zaikokuji R, Morishita K,  
304            Tomita H, Oda K *et al*: **Neutrophil Elastase Damages the Pulmonary Endothelial**  
305            **Glycocalyx in Lipopolysaccharide-Induced Experimental Endotoxemia.** *Am J Pathol*  
306            2019, **189(8):1526-1535.**
- 307    14.        Suda K, Takeuchi H, Hagiwara T, Miyasho T, Okamoto M, Kawasaki K, Yamada S,  
308            Suganuma K, Wada N, Saikawa Y *et al*: **Neutrophil elastase inhibitor improves survival of**  
309            **rats with clinically relevant sepsis.** *Shock* 2010, **33(5):526-531.**
- 310    15.        Hagiwara S, Iwasaka H, Togo K, Noguchi T: **A neutrophil elastase inhibitor, sivelestat,**  
311            **reduces lung injury following endotoxin-induced shock in rats by inhibiting HMGB1.**  
312            *Inflammation* 2008, **31(4):227-234.**
- 313    16.        Gao X, Zhang R, Lei Z, Guo X, Yang Y, Tian J, Huang L: **Efficacy, safety, and**  
314            **pharmacoeconomics of sivelestat sodium in the treatment of septic acute respiratory**  
315            **distress syndrome: a retrospective cohort study.** *Ann Palliat Med* 2021,  
316            **10(11):11910-11917.**
- 317    17.        Hayakawa M, Katabami K, Wada T, Sugano M, Hoshino H, Sawamura A, Gando S:  
318            **Sivelestat (selective neutrophil elastase inhibitor) improves the mortality rate of sepsis**  
319            **associated with both acute respiratory distress syndrome and disseminated**  
320            **intravascular coagulation patients.** *Shock* 2010, **33(1):14-18.**
- 321    18.        Miyoshi S, Hamada H, Ito R, Katayama H, Irifune K, Suwaki T, Nakanishi N, Kanematsu T,  
322            Dote K, Aibiki M *et al*: **Usefulness of a selective neutrophil elastase inhibitor, sivelestat, in**  
323            **acute lung injury patients with sepsis.** *Drug Des Devel Ther* 2013, **7:305-316.**
- 324    19.        Shankar-Hari M, Phillips GS, Levy ML, Seymour CW, Liu VX, Deutschman CS, Angus DC,  
325            Rubenfeld GD, Singer M: **Developing a New Definition and Assessing New Clinical**  
326            **Criteria for Septic Shock: For the Third International Consensus Definitions for Sepsis**  
327            **and Septic Shock (Sepsis-3).** *Jama* 2016, **315(8):775-787.**
- 328    20.        Thompson BT, Chambers RC, Liu KD: **Acute Respiratory Distress Syndrome.** *N Engl J*  
329            *Med* 2017, **377(6):562-572.**
- 330    21.        Tamakuma S, Ogawa M, Aikawa N, Kubota T, Hirasawa H, Ishizaka A, Taenaka N, Hamada

- 331 C, Matsuoka S, Abiru T: **Relationship between neutrophil elastase and acute lung injury**  
332 **in humans.** *Pulm Pharmacol Ther* 2004, **17**(5):271-279.
- 333 22. Zeiher BG, Artigas A, Vincent JL, Dmitrienko A, Jackson K, Thompson BT, Bernard G:  
334 **Neutrophil elastase inhibition in acute lung injury: results of the STRIVE study.** *Crit*  
335 *Care Med* 2004, **32**(8):1695-1702.
- 336 23. Aikawa N, Kawasaki Y: **Clinical utility of the neutrophil elastase inhibitor sivelestat for**  
337 **the treatment of acute respiratory distress syndrome.** *Ther Clin Risk Manag* 2014,  
338 **10**:621-629.
- 339 24. Mohamed MMA, El-Shimy IA, Hadi MA: **Neutrophil Elastase Inhibitors: A potential**  
340 **prophylactic treatment option for SARS-CoV-2-induced respiratory complications?** *Crit*  
341 *Care* 2020, **24**(1):311.
- 342 25. Denning NL, Aziz M, Gurien SD, Wang P: **DAMPs and NETs in Sepsis.** *Front Immunol*  
343 2019, **10**:2536.
- 344 26. Fei Y, Huang X, Ning F, Qian T, Cui J, Wang X, Huang X: **NETs induce ferroptosis of**  
345 **endothelial cells in LPS-ALI through SDC-1/HS and downstream pathways.** *Biomed*  
346 *Pharmacother* 2024, **175**:116621.
- 347 27. Matsuzaki K, Hiramatsu Y, Homma S, Sato S, Shigeta O, Sakakibara Y: **Sivelestat reduces**  
348 **inflammatory mediators and preserves neutrophil deformability during simulated**  
349 **extracorporeal circulation.** *Ann Thorac Surg* 2005, **80**(2):611-617.
- 350 28. Pan T, Tuoerxun T, Chen X, Yang CJ, Jiang CY, Zhu YF, Li ZS, Jiang XY, Zhang HT, Zhang  
351 H *et al*: **The neutrophil elastase inhibitor, sivelestat, attenuates acute lung injury in**  
352 **patients with cardiopulmonary bypass.** *Front Immunol* 2023, **14**:1082830.
- 353 29. Li J, Qi Z, Li D, Huang X, Qi B, Feng J, Qu J, Wang X: **Alveolar epithelial glycocalyx**  
354 **shedding aggravates the epithelial barrier and disrupts epithelial tight junctions in acute**  
355 **respiratory distress syndrome.** *Biomed Pharmacother* 2021, **133**:111026.
- 356 30. Liu XY, Xu HX, Li JK, Zhang D, Ma XH, Huang LN, Lü JH, Wang XZ: **Neferine Protects**  
357 **Endothelial Glycocalyx via Mitochondrial ROS in Lipopolysaccharide-Induced Acute**  
358 **Respiratory Distress Syndrome.** *Front Physiol* 2018, **9**:102.
- 359  
360

361

362

363

364

365

366

367 Table 1. Baseline characteristics of the study subjects.

368 Table 2. Trial outcomes. CI denotes confidence interval. SD denotes standard deviation. IQR

369 denotes interquartile range. ICU denotes intensive care unit. # calculated in patients undergoing

370 mechanical ventilation at randomization; \*calculated in patients admitted in ICU at randomization.

371 §Difference was shown for continuous variables and risk ratio was shown for categorical

372 variables.

373 Table S1. Numbers of cases from each site.

374

375 Figure 1. Study flowchart.

376 Figure 2. Survival curve. HR denotes hazard ratio. CI denotes confidence interval.


377 Figure 3. Subgroup analysis for the primary outcome. RD denotes risk difference. CI denotes

378 confidence interval. APACHE II denotes Acute Physiology and Chronic Health Evaluation II.

379 Figure S1. Cumulative event of weaning from mechanical ventilation. HR denotes hazard ratio. CI

380 denotes confidence interval.


Treatment + Control + Sivelestat




Number at risk

Treatment	0	5	10	15	20	25	30
Control	36	22	12	12	11	11	0
Sivelestat	34	15	8	7	7	5	0

## CONSORT 2010 Flow Diagram





Number at risk

Treatment	0	5	10	15	20	25	30
Control	36	36	31	30	28	25	0
Sivelestat	34	34	33	31	31	31	0





**Table S1. Numbers of cases from each site**

Participating sites	Total	Sivelestat group (N=34)	Control group (N=36)
Liaocheng People's Hospital	13	6	7
Affiliated Hospital of Binzhou Medical College	12	6	6
The First Affiliated Hospital of Shandong First Medical University	13	6	7
Provincial Hospital of Shandong First Medical University	18	9	9
Linyi People's Hospital	7	3	4
Qilu Hospital of Shandong University	4	2	2
Qingdao Municipal Hospital	1	1	0
Tai'an Central Hospital	1	0	1
Shandong Public Health Clinical Centre	1	1	0
Total cases	70	34	36

Table 1. Baseline characteristics of the study subjects.

Characteristics	Sivelestat group (N=34)	Placebo group (N=36)
Mean Age±SD, yr	61.2±11.4	56.5±17.6
Gender, n (%)		
Women	12 (35.3)	13 (36.1)
Men	22 (64.7)	23 (63.9)
Mean BMI±SD, kg/m <sup>2</sup>	25.0±4.4	25.5±3.6
Median Charlson score (IQR)	4.0 (2.5-5.0)	5.0 (2.5-5.5)
Comorbidities, no. (%)		
Hypertension	15 (44.1)	11 (30.6)
Diabetes mellitus	11 (32.4)	4 (11.1)
Coronary heart disease	6 (17.6)	4 (11.1)
History of covid-19 infection, n (%)	4 (11.8)	8 (22.2)
Use of mechanical ventilation, n (%)	25 (73.5)	27 (75.0)
Ventilator related parameters, median (IQR)		
Lung compliance, ml/cmH <sub>2</sub> O	51.0 (30.8-58.5)	39.3 (33.2-48.4)
Positive end-expiratory pressure at randomization, cmH <sub>2</sub> O	5 (5-8)	5 (5-8)
Clinical parameters		
Presence of sepsis, no. (%)	34 (100.0)	35 (97.2)
Presence of septic shock, no. (%)	16 (47.1)	15 (41.7)
Median APACHE II score (IQR)	20.5 (12.0-25.0)	17.5 (11.3-24.0)
Median SOFA score (IQR)	7.0 (4.8-10.0)	6.0 (4.3-9.8)
Median lac (IQR), mmol/L	1.2 (1.0-2.8)	1.4 (1.0-1.8)
Median PaO <sub>2</sub> /FiO <sub>2</sub> ratio (IQR)	136.0 (104.2-163.0)	161.0 (144.0-195.0)
Laboratory parameters, median (IQR)		
Serum NE concentration, pg/ml, ×10 <sup>4</sup>	31.0 (7.8-35.5)	32.7 (15.6-37.7)

Table 2. Trial outcomes.

	Sivelestat group (N=34)	Placebo group (N=36)	Difference/ Risk ratio <sup>§</sup> (95% CI)	P value
Primary outcome				
PaO <sub>2</sub> /FiO <sub>2</sub> ratio improvement on day5, n (%)	19 (55.9)	7 (19.4)	0.36 (0.14, 0.56)	<0.001
Secondary outcomes				
PaO <sub>2</sub> /FiO <sub>2</sub> ratio				
Day 3, mean±SD	252.1±78.5	169.4±64.6	82.7 (49.1, 116.3)	
Day 5, mean±SD	261.8±68.4	173.7±69.2	88.1 (54.6, 121.6)	
Day 7, mean±SD	270.1±82.6	201.3±85.0	68.8 (16.8, 120.7)	
Ventilator free days within 28 days, d, median (IQR) <sup>#</sup>	21.0 (6.5, 24.5)	20.0 (0, 23.0)	3.9 (-1.9, 9.7)	0.20
28-day ICU free days, d, median (IQR)*	17.0 (0, 20.5)	10.0 (0, 21.3)	2.2 (-3.4, 7.7)	0.45
28-day hospital free days, d, median (IQR)	9.0 (0, 15.3)	9.5 (0, 17.8)	-1.3 (-5.2, 2.6)	0.52
28-day mortality, n (%)	3 (8.8)	10 (27.8)	-0.19 (-0.37, -0.01)	0.03
Adverse events				
Hematological Abnormalities, no.	2	2		
Abnormal liver function, no.	1	2		

Hyperuricaemia, no.	0	1
Hyperlactacidemia, no.	0	1

---

CI denotes confidence interval. SD denotes standard deviation. IQR denotes interquartile range. ICU denotes intensive care unit. # calculated in patients undergoing mechanical ventilation at randomization; \* calculated in patients admitted in ICU at randomization. <sup>§</sup>Difference was shown for continuous variables and risk ratio was shown for categorical variables.

Effect of Neutrophil Elastase Inhibitor (Sivelestat Sodium) on Oxygenation in Patients with Sepsis Induced Mild to Moderate Acute Respiratory Distress Syndrome

Tiejun Wu<sup>1#\*</sup>, Tao Wang<sup>2#</sup>, Jinjiao Jiang<sup>3</sup>, Yue Tang<sup>3</sup>, Lina Zhang<sup>1</sup>, Zhiming Jiang<sup>4</sup>, Fen Liu<sup>4</sup>, Guiqing Kong<sup>2</sup>, Tingfa Zhou<sup>5</sup>, Ruijin Liu<sup>5</sup>, Haipeng Guo<sup>6</sup>, Jie Xiao<sup>6</sup>, Wenqing Sun<sup>7</sup>, Yuye Li<sup>7</sup>, Yingying Zhu<sup>8</sup>, Quan Liu<sup>8</sup>, Weifeng Xie<sup>9</sup>, Yan Qu<sup>9</sup>, Xiaozhi Wang<sup>2\*</sup>.

1. Department of Critical Care Medicine, Liaocheng People's Hospital, Liaocheng 252004, China.
2. Department of Critical Care Medicine, Affiliated Hospital of Binzhou Medical College, Binzhou 256699, China.
3. Department of Critical Care Medicine, Provincial Hospital of Shandong First Medical University, Jinan 250021, China.
4. Department of Critical Care Medicine, The First Affiliated Hospital of Shandong First Medical University, Jinan 250013, China.
5. Department of Critical Care Medicine, Linyi People's Hospital, Linyi 276034, China.
6. Department of Critical Care Medicine, Qilu Hospital of Shandong University, Jinan 250012, China.
7. Department of Respiratory intensive care unit, Shandong Public Health Clinical Centre, Jinan 250102, China.
8. Department of Critical Care Medicine, Tai'an Central Hospital, Taian 271002, China.
9. Department of Critical Care Medicine, Qingdao Municipal Hospital, Qingdao 266071, China.

# These authors contributed equally to this work.

\* Corresponding author,

Xiaozhi Wang Email: [hxicuwxz@163.com](mailto:hxicuwxz@163.com).

Tiejun Wu Email: [tiejunwu@hotmail.com](mailto:tiejunwu@hotmail.com)

### Ethical approval

Organization	Ethical state	Number (no.)	Date
Liaocheng People's Hospital	Approve	2022021	2022-02-15
Affiliated Hospital of Binzhou Medical College	Approve	2022-015-1	2022-03-10
Provincial Hospital of Shandong First Medical University	Approve	2022-144	2022-04-13
The First Affiliated Hospital of Shandong First Medical University	Approve	YXLL-KY-2022(046)	2022-06-01
Linyi People's Hospital	Approve	YX200375	2022-04-29
Qilu Hospital of Shandong University	Approve	KYLL-2022B-014	2022-04-24
Shandong Public Health Clinical Centre	Approve	GWLCZXEC 2022-84	2022-09-13
Tai'an Central Hospital	Approve	2022-06-22	2022-06-22
Qingdao Municipal Hospital	Approve	2022-06-30	2022-06-30